Iovance Biotherapeutics, Inc. IOVA R2K

Healthcare · Biotechnology · United States

https://www.iovance.com

Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It also develops lifileucel for the treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma (HNSCC); LN-145-S1 to treat melanoma and HNSCC; LN-145 Gen 3 and core biopsy for the treatment of NSCLC; LN-145 Gen 3 to treat melanoma and HNSCC; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001 for use in the TIL therapy treatment regimen. The company has collaborations and licensing agreements with National Institutes of Health; the National Cancer Institute; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Market & Price

Market Cap

$1.83B

Current Price

$4.10

High / Low (52W)

$5.41 / $1.69

Beta

0.69

Valuation

Stock P/E

Industry PE

23.65

Forward P/E

PEG Ratio

Book Value

$1.65

Price to Book

2.49

P/S

6.41

EV/EBITDA

-4.87

Dividend Yield

Profitability & Returns

ROCE

-51.39%

ROE

-47.51%

ROA

-23.65%

Profit Margin

Op Margin

EPS (Latest Qtr)

$-0.19

EPS (TTM)

$-0.92

Balance Sheet & Liquidity

Debt/Equity

0.07

Quick Ratio

3.05

Current Ratio

3.60

Debt

$47.78M

Total Assets

$913.17M

Current Assets

$442.69M

Working Capital

$304.33M

Ownership

Promoter Holding

0.33%

Chg in Prom Hold

FII / Inst Holding

67.47%

Chg in FII Hold

Financial Snapshot

Enterprise Value

$1.56B

Total Revenue (TTM)

$285.61M

EBITDA

$-321.62M

Free Cash Flow

$-149.07M

Operating Cash Flow

$-270.79M

Shares Outstanding

446.50M

Gross Margin

39.44%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

Profit 5Y

0.41%

Revenue (YoY)

44.80%

Earnings (YoY)

PROS

In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	IOVA Iovance Biotherapeutics, Inc. R2K	4.10	-	$1.83B	-	-51.39%	-47.51%	-	0.41%
2	LLY Eli Lilly and Company SPX	1,105.00	39.21	$985.37B	0.63%	38.44%	107.46%	31.69%	48.96%
3	JNJ Johnson & Johnson SPX	225.33	26.11	$542.42B	2.38%	23.13%	26.42%	5.60%	14.32%
4	UNH UnitedHealth Group Incorporated SPX	380.31	28.66	$345.38B	2.32%	9.60%	12.18%	11.35%	-15.69%
5	MRK Merck & Co., Inc. SPX	118.72	33.44	$293.22B	2.86%	20.66%	18.94%	3.12%	7.93%
6	TMO Thermo Fisher Scientific Inc. SPX	492.51	27.11	$183.03B	0.38%	9.17%	13.52%	-0.27%	-1.19%
7	AMGN Amgen Inc. NDXSPX	336.79	23.42	$181.77B	2.99%	18.02%	101.32%	11.77%	5.58%
8	GILD Gilead Sciences, Inc. NDXSPX	134.43	18.29	$166.90B	2.44%	22.92%	43.36%	2.57%	22.83%
9	ISRG Intuitive Surgical, Inc. NDXSPXAI	424.64	51.53	$150.39B	-	15.96%	17.23%	17.39%	29.26%

Quarterly Results

Figures in USD.

Metric	Jun 2015	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	238.00K	469.00K	715.00K	31.11M	58.55M	49.32M	59.95M	67.45M	86.77M	71.43M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	42.72M	56.66M	38.48M	43.11M	42.50M
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6.61M	3.29M	28.98M	43.66M	28.93M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	127.83M	117.06M	118.74M	117.12M	109.97M
Operating Income	-6.44M	-7.64M	-	-7.01M	-11.73M	-18.98M	-	-20.88M	-23.58M	-22.34M	-	-26.88M	-31.38M	-35.06M	-	-39.99M	-50.16M	-51.61M	-	-70.81M	-63.63M	-58.97M	-	-75.57M	-81.43M	-86.24M	-91.71M	-99.73M	-100.39M	-110.86M	-110.09M	-118.36M	-117.72M	-101.91M	-89.07M	-121.22M	-113.77M	-89.76M	-73.46M	-81.04M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-110.29M	-101.71M	-78.08M	-60.82M	-70.63M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-118.00M	-109.67M	-93.66M	-71.72M	-79.71M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1.84M	1.99M	-2.40M	184.00K	-665.00K
Net Income	-6.37M	-7.63M	-8.36M	-6.88M	-11.56M	-68.21M	-15.69M	-20.68M	-23.38M	-22.15M	-25.85M	-26.52M	-30.66M	-33.83M	-32.58M	-36.95M	-47.55M	-49.49M	-63.57M	-69.59M	-63.02M	-58.57M	-68.40M	-75.45M	-81.35M	-86.12M	-91.61M	-99.35M	-99.62M	-107.37M	-106.53M	-113.76M	-112.98M	-97.10M	-83.54M	-116.16M	-111.66M	-91.25M	-71.90M	-79.05M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.47	-0.40	-	-0.51	-0.53	-0.55	-0.58	-0.63	-0.63	-0.50	-0.47	-0.46	-0.42	-0.34	-0.28	-0.36	-0.33	-0.25	-0.18	-0.19
R&D Expense	4.05M	4.96M	-	4.19M	4.46M	8.48M	-	15.59M	18.65M	16.68M	-	19.91M	24.55M	27.95M	-	30.91M	39.30M	41.58M	-	56.95M	49.27M	43.05M	-	55.95M	62.12M	65.36M	68.30M	73.41M	72.50M	82.73M	86.35M	87.53M	79.78M	62.08M	67.04M	75.97M	79.36M	75.17M	-	62.49M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	1.19M	164.07M	263.50M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	1.03M	93.25M	173.18M
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	156.00K	70.82M	90.32M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	398.88M	460.71M	466.10M	488.53M
Operating Income	-	-15.77K	-815.41K	-21.22M	-8.13M	-22.64M	-12.04M	-27.86M	-53.64M	-92.88M	-128.26M	-206.87M	-261.94M	-	-398.88M	-460.56M	-395.28M	-398.21M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-377.74M	-427.43M	-347.21M	-350.89M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-395.89M	-447.52M	-375.00M	-393.05M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-3.48M	-2.83M	-2.07M
Net Income	-58.72K	-15.77K	-1.61M	-25.69M	-3.31M	-25.38M	-12.04M	-27.66M	-52.89M	-92.06M	-123.58M	-197.56M	-259.58M	-	-395.89M	-444.04M	-372.18M	-390.98M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-	-1.59	-1.88	-	-2.49	-1.89	-1.28	-1.09
R&D Expense	-	0	171.48K	1.76M	1.66M	2.15M	3.85M	15.47M	26.94M	71.61M	99.83M	166.02M	201.73M	259.04M	294.78M	333.19M	276.23M	300.27M

Compounded Sales Growth

5 Years:	-
1 Year:	44.80%

Compounded Profit Growth

5 Years:	0.41%
1 Year:	-

Stock Price Performance

1 Year:	+134.29%
6 Months:	+65.32%
3 Months:	+6.22%
1 Month:	+23.87%

Balance Sheet (Annual)

Figures in USD.

Metric	Sep 2007	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	-	-	1.46M	568.43K	29.41K	19.87M	46.51M	105.65M	171.89M	155.37M	480.82M	344.65M	768.46M	-	663.98M	780.35M	910.43M	913.17M
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	479.12M	307.85M	457.02M	442.69M
Cash & Equivalents	0	0	2.90K	8.26K	1.29M	510.22K	0	19.67M	44.91M	33.59M	106.72M	145.37M	82.15M	13.97M	67.33M	-	231.73M	114.89M	115.69M	163.08M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	10.37M	51.52M	51.68M
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	151.00K	69.34M	82.45M
Total Liabilities	-	-	-	-	-	-	-	-	-	-	-	9.89M	14.63M	45.68M	111.96M	-	164.34M	195.74M	200.02M	214.59M
Current Liabilities	-	-	-	-	822.87K	13.35M	11.35M	2.27M	1.66M	1.63M	4.97M	9.60M	14.40M	39.08M	54.87M	-	91.48M	110.31M	122.34M	138.36M
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.00M	1.00M	1.00M	1.00M	-
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	85.45M	75.86M	58.26M	49.44M
Total Equity	8.00K	61.00K	2.28K	-13.49K	638.09K	-12.78M	-11.32M	17.60M	44.84M	104.02M	166.92M	145.48M	466.19M	298.97M	656.50M	-	499.64M	584.61M	710.40M	698.58M
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	187.81M	256.14M	305.25M	411.94M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-14.45K	-620.80K	-6.19M	-2.24M	-3.66M	8.63M	-18.38M	-32.67M	-78.71M	-101.25M	-158.89M	-205.13M	-	-292.76M	-361.82M	-352.98M	-302.41M
Investing Cash Flow	0	0	-81.05K	0	-12.71K	-	-71.21M	8.89M	58.68M	-386.28M	90.03M	-317.85M	-	256.45M	-155.24M	-96.41M	47.50M
Financing Cash Flow	19.80K	1.91M	5.49M	1.73M	23.35M	-	78.27M	96.90M	58.69M	424.31M	6.13M	576.42M	-	190.15M	462.96M	390.66M	300.77M
Capital Expenditure	-0	-0	-31.05K	-0	-13.00K	-1.59M	-1.14M	-1.52M	-1.03M	-1.20M	-6.92M	-46.79M	-	-20.43M	-22.29M	-11.07M	-33.84M
Free Cash Flow	-14.45K	-620.80K	-6.22M	-2.24M	-3.68M	7.04M	-19.52M	-34.19M	-79.74M	-102.45M	-165.81M	-251.93M	-	-313.18M	-384.11M	-364.05M	-336.24M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-	-	-	-	153.85M	-54.10M	-58.72M	45.86M

Ratios (Annual)

Figures in %.

Metric	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	13.1%	43.2%	34.3%
Operating Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-38,735.0%	-240.9%	-151.1%
Net Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-37,345.4%	-226.8%	-148.4%
ROE %	-2,570.8%	116.9%	-252.0%	201.0%	29.2%	-144.2%	-26.8%	-26.6%	-31.7%	-63.3%	-26.5%	-66.1%	-39.5%	-	-79.2%	-76.0%	-52.4%	-56.0%
ROCE %	-	-	-127.8%	166.0%	71.8%	-128.6%	-26.9%	-26.8%	-32.1%	-63.7%	-27.5%	-67.7%	-36.7%	-	-69.7%	-68.7%	-50.2%	-51.4%

Shareholding Pattern

Insiders

0.33%

Institutions

67.47%

Public Float

67.70%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	6.96%	31.08M	$127.43M
2	MHR Fund Management, LLC	6.49%	28.97M	$118.77M
3	State Street Corporation	3.91%	17.45M	$71.54M
4	Vanguard Capital Management LLC	3.72%	16.62M	$68.13M
5	Two Sigma Investments, LP	3.07%	13.69M	$56.12M
6	Vanguard Portfolio Management LLC	2.62%	11.70M	$47.97M
7	Millennium Management Llc	2.11%	9.41M	$38.60M
8	Goldman Sachs Group Inc	1.96%	8.76M	$35.92M
9	Geode Capital Management, LLC	1.92%	8.57M	$35.15M
10	Invenomic Capital Management, LP	1.90%	8.50M	$34.83M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for IOVA

No recent headlines available.

IOVA · Healthcare